Hong Kong Stock Movement: CLOUDBREAK-B fell 11.53%, market concerns arise from the extension of the lock-up period and equity incentives

Hong Kong Stock Movement CLOUDBREAK-B fell 11.53%. Based on recent key news: On January 2, cornerstone investor FuCe Holdings voluntarily extended the lock-up period until July 2, 2026, holding a 1.84% stake. This move indicates investor confidence in the company's future prospects, but the market reacted poorly, leading to a decline in stock price. On January 3, CLOUDBREAK-B issued and allocated 1.785 million shares under the equity incentive plan, increasing the number of shares in circulation, which may exert pressure on the stock price. On January 2, shareholders deposited stocks with GF Securities Hong Kong, with a market value of HKD 1.605 billion, accounting for 36.55%, which may raise concerns about market liquidity. The Hong Kong market has recently experienced increased volatility, necessitating attention to risks. Stocks with High Trading Volume in the Industry Innovent Biologics rose 6.60%. Based on recent key news: On January 5, Daiwa published a report indicating a comprehensive rise in the Chinese biopharmaceutical sector and raised the target price for Innovent Biologics to HKD 112, driving the stock price up. Daiwa believes Innovent Biologics is a high-quality target and recommends investors pay attention to its clinical data release points and stock price catalysts. On January 3, Innovent Biologics' Chief R&D Officer Qian Lei stated that the Chinese biopharmaceutical market will gradually align with global standards, enhancing market confidence. Innovent Biologics' continued investment and R&D capabilities in innovative drugs have been recognized, further driving the stock price up. Recently, the market size of China's innovative drug sector has surpassed RMB 120 billion, demonstrating strong growth potential. As an industry leader, Innovent Biologics benefits from market recognition and capital support for innovative drugs, resulting in a rise in stock price. The biopharmaceutical sector has shown strong performance, with significant capital inflow. 3SBio rose 5.45%. Based on recent key news: On January 5, Guoyuan Securities maintained a buy rating for 3SBio, with a target price of HKD 32.76. Analysts unanimously consider 3SBio a strong buy, with an average target price of HKD 42.69, driving the stock price up. On January 2, a report from CMB International pointed out that the mainland market has entered a period of policy validation and profit recovery, with 3SBio listed as one of the key stocks to watch in January, attracting investor attention. On January 5, the total amount of external licensing transactions by Chinese biotechnology companies exceeded USD 123 billion, showing significant growth compared to 2024, highlighting the industry's strong potential for international cooperation and boosting market confidence. The innovative drug sector enjoys policy support, with noticeable capital inflow. BeiGene rose 6.02%. Based on recent key news: On January 5, the Hang Seng Medical ETF surged 5.1%, benefiting innovative drug companies like BeiGene from the commercial insurance catalog and the advantages of the Hong Kong Stock Exchange system, driving the stock price up. The Hang Seng Medical ETF focuses on innovative drugs, and due to the influence of the commercial insurance catalog and the Hong Kong Stock Exchange 18A system advantages, BeiGene's stock price rose 6.02%. Source: Daily Economic News On January 4th, China's innovative drug industry policy support has increased, promoting the development of the innovative drug market. The National Medical Products Administration has clearly stated that it will introduce more measures to accelerate the rapid development of innovative drugs, benefiting BeiGene as an innovative drug company. Source: Zhitong Finance On January 2nd, the inhibition of the TIGIT protein is expected to assist the immune system in targeting cancer cells, and BeiGene's related research has attracted market attention. Cell Death Dis reported on the research progress of inhibiting the TIGIT protein, enhancing BeiGene's market visibility. Source: CaiLianShe, the innovative drug sector shows high prosperity, with significant capital inflow. Stocks ranked among the top in industry market capitalization Kangfang Biotech rose by 3.62%. Based on recent key news: On January 5th, Daiwa published a report stating that Kangfang Biotech lacks short-term catalysts, downgrading its rating from "Buy" to "Hold." Nevertheless, the forecast for authorized revenue from global sales of Yivofex has been raised, with the target price increased from HKD 100 to HKD 116. This news has driven up Kangfang Biotech's stock price. There have been no other significant news recently. The Hong Kong stock market has been quite volatile lately and requires attention